Stifel upgraded C.H. Robinson (CHRW) to Buy from Hold with an unchanged price target of $113. The company reported “solid” Q4 results and the ...

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

JMP Securities raised the firm’s price target on Stifel Financial (SF) to $135 from $125 and keeps an Outperform rating on the shares. Stifel ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Stifel's commentary also mentioned that C.H. Robinson has been considered a "show-me story," indicating that the market has been waiting for proof of the company's performance and strategy ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.

Colgate-Palmolive Co (CL) stock saw a decline, ending the day at $89.57 which represents a decrease of $-0.29 or -0.32% from the prior close of $89.86. The stock opened at $90.11 and touched a low of ...

The Financial Conduct Authority (FCA) has been warned that some investors would no longer funnel their capital into the investment companies sector if the regulator proceeds with some of its proposals ...

The natural beauty of West Virginia will be celebrated both musically and visually in the Wheeling Symphony Orchestra’s upcoming performance, “Nature. Beauty.” Set for 2 p.m., Feb. 8, at the Capitol ...